Published in Mol Ther on December 08, 2009
Satellite cells and the muscle stem cell niche. Physiol Rev (2013) 3.40
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol (2012) 2.50
Reprogramming cellular identity for regenerative medicine. Cell (2012) 1.71
Generation of induced pluripotent stem cells in rabbits: potential experimental models for human regenerative medicine. J Biol Chem (2010) 1.37
Human artificial chromosomes for gene delivery and the development of animal models. Mol Ther (2011) 1.30
Human artificial chromosome with a conditional centromere for gene delivery and gene expression. DNA Res (2010) 1.29
Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther (2010) 1.23
Human artificial chromosome (HAC) vector with a conditional centromere for correction of genetic deficiencies in human cells. Proc Natl Acad Sci U S A (2011) 1.21
The challenge of immunogenicity in the quest for induced pluripotency. Nat Rev Immunol (2010) 1.14
Integration-free iPS cells engineered using human artificial chromosome vectors. PLoS One (2011) 1.13
Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol (2012) 1.09
Generation of skeletal muscle cells from embryonic and induced pluripotent stem cells as an in vitro model and for therapy of muscular dystrophies. J Cell Mol Med (2012) 1.08
A new generation of human artificial chromosomes for functional genomics and gene therapy. Cell Mol Life Sci (2012) 1.06
New lessons learned from disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev (2012) 1.04
Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. Cell Mol Life Sci (2010) 1.01
Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol (2015) 1.00
Organization of synthetic alphoid DNA array in human artificial chromosome (HAC) with a conditional centromere. ACS Synth Biol (2012) 0.99
Putting CENP-A in its place. Cell Mol Life Sci (2012) 0.99
Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays (2012) 0.98
Reprogramming efficiency and quality of induced Pluripotent Stem Cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages. PLoS Curr (2011) 0.96
What can pluripotent stem cells teach us about neurodegenerative diseases? Nat Neurosci (2010) 0.93
Induced pluripotent stem cells in the study of neurological diseases. Stem Cell Res Ther (2011) 0.93
A pathway from chromosome transfer to engineering resulting in human and mouse artificial chromosomes for a variety of applications to bio-medical challenges. Chromosome Res (2015) 0.92
Retargeting of microcell fusion towards recipient cell-oriented transfer of human artificial chromosome. BMC Biotechnol (2015) 0.91
Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin (2013) 0.89
Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp Neurol (2014) 0.89
Patient-specific pluripotent stem cells in neurological diseases. Stem Cells Int (2011) 0.88
Induced pluripotent stem cells as a next-generation biomedical interface. Lab Invest (2011) 0.87
Stable maintenance of de novo assembled human artificial chromosomes in embryonic stem cells and their differentiated progeny in mice. Cell Cycle (2015) 0.87
A novel system for simultaneous or sequential integration of multiple gene-loading vectors into a defined site of a human artificial chromosome. PLoS One (2014) 0.86
Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front Physiol (2014) 0.86
Moving toward a higher efficiency of microcell-mediated chromosome transfer. Mol Ther Methods Clin Dev (2016) 0.85
Coaxing stem cells for skeletal muscle repair. Adv Drug Deliv Rev (2014) 0.84
Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. PLoS One (2014) 0.84
From pluripotency to myogenesis: a multistep process in the dish. J Muscle Res Cell Motil (2015) 0.84
Generation of a conditionally self-eliminating HAC gene delivery vector through incorporation of a tTAVP64 expression cassette. Nucleic Acids Res (2015) 0.83
The pharmacology of regenerative medicine. Pharmacol Rev (2013) 0.83
Gene correction in patient-specific iPSCs for therapy development and disease modeling. Hum Genet (2016) 0.83
Highly Efficient Transfer of Chromosomes to a Broad Range of Target Cells Using Chinese Hamster Ovary Cells Expressing Murine Leukemia Virus-Derived Envelope Proteins. PLoS One (2016) 0.82
The transfer of human artificial chromosomes via cryopreserved microcells. Cytotechnology (2013) 0.82
Protecting a transgene expression from the HAC-based vector by different chromatin insulators. Cell Mol Life Sci (2013) 0.82
PTK7 marks the first human developmental EMT in vitro. PLoS One (2012) 0.81
Complete restoration of multiple dystrophin isoforms in genetically corrected Duchenne muscular dystrophy patient-derived cardiomyocytes. Mol Ther Methods Clin Dev (2014) 0.80
Human first-trimester chorionic villi have a myogenic potential. Cell Tissue Res (2012) 0.80
Re-engineering an alphoid(tetO)-HAC-based vector to enable high-throughput analyses of gene function. Nucleic Acids Res (2013) 0.80
piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucleic Acids Res (2015) 0.79
Human iPSCs Differentiate Into Functional MSCs and Repair Bone Defects. Stem Cells Transl Med (2016) 0.79
Induced pluripotent stem cells for modeling neurological disorders. World J Transplant (2015) 0.79
Bi-HAC vector system toward gene and cell therapy. ACS Synth Biol (2014) 0.79
Development of a Safeguard System Using an Episomal Mammalian Artificial Chromosome for Gene and Cell Therapy. Mol Ther Nucleic Acids (2015) 0.78
Stem cell transplantation for treating Duchenne muscular dystrophy: A Web of Science-based literature analysis. Neural Regen Res (2012) 0.78
The promise of human induced pluripotent stem cells in dental research. Stem Cells Int (2012) 0.77
A Perspective on the Potential of Human iPS Cell-Based Therapies for Muscular Dystrophies: Advancements so far and Hurdles to Overcome. J Stem Cell Res Ther (2013) 0.77
Cell replacement therapies: is it time to reprogram? Hum Gene Ther (2014) 0.77
Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes. Chromosome Res (2015) 0.77
Evaluation of an Hprt-Luciferase Reporter Gene on a Mammalian Artificial Chromosome in Response to Cytotoxicity. Yonago Acta Med (2016) 0.77
Differential requirement for utrophin in the induced pluripotent stem cell correction of muscle versus fat in muscular dystrophy mice. PLoS One (2011) 0.77
The Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases. Curr Protoc Toxicol (2016) 0.76
Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy. J Biomed Biotechnol (2010) 0.76
Enhanced Reprogramming Efficiency and Kinetics of Induced Pluripotent Stem Cells Derived from Human Duchenne Muscular Dystrophy. PLoS Curr (2015) 0.76
Induced pluripotent stem (iPS) cells offer a powerful new tool for the life sciences. J Stem Cells Regen Med (2010) 0.75
DYS-HAC-iPS cells: the combination of gene and cell therapy to treat duchenne muscular dystrophy. Mol Ther (2010) 0.75
CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy. Mol Ther Nucleic Acids (2017) 0.75
Genome Editing Gene Therapy for Duchenne Muscular Dystrophy. J Neuromuscul Dis (2015) 0.75
Engineering cell-based therapies to interface robustly with host physiology. Adv Drug Deliv Rev (2016) 0.75
Transgene expression and differentiation of baculovirus-transduced adipose-derived stem cells from dystrophin-utrophin double knock-out mouse. Neural Regen Res (2012) 0.75
Disease modeling using human induced pluripotent stem cells: lessons from the liver. Biochim Biophys Acta (2014) 0.75
De novo myocardial regeneration: advances and pitfalls. Antioxid Redox Signal (2010) 0.75
Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies? J Neuromuscul Dis (2016) 0.75
Cellular Reprogramming Using Defined Factors and MicroRNAs. Stem Cells Int (2016) 0.75
Replication of somatic micronuclei in bovine enucleated oocytes. Cell Div (2012) 0.75
CRISPR/Cas9-induced transgene insertion and telomere-associated truncation of a single human chromosome for chromosome engineering in CHO and A9 cells. Sci Rep (2017) 0.75
Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. Stem Cells Int (2017) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Embryonic stem cell lines derived from human blastocysts. Science (1998) 65.53
Establishment in culture of pluripotential cells from mouse embryos. Nature (1981) 30.49
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Human induced pluripotent stem cells free of vector and transgene sequences. Science (2009) 17.16
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell (1987) 16.01
Generation of mouse induced pluripotent stem cells without viral vectors. Science (2008) 15.25
Induced pluripotent stem cells generated without viral integration. Science (2008) 13.38
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science (2007) 12.41
Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell (2009) 11.65
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature (2009) 11.27
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell (1988) 10.75
Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature (2009) 9.29
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature (2009) 5.37
Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell (2008) 4.63
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med (2007) 2.61
Inactivation of a human kinetochore by specific targeting of chromatin modifiers. Dev Cell (2008) 2.50
Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med (2008) 2.38
Functional expression and germline transmission of a human chromosome fragment in chimaeric mice. Nat Genet (1997) 2.28
The cardiomyopathy of progressive muscular dystrophy. Circulation (1966) 2.21
Upping the ante: recent advances in direct reprogramming. Mol Ther (2009) 1.73
The subcellular distribution of dystrophin in mouse skeletal, cardiac, and smooth muscle. J Cell Biol (1991) 1.59
Dystrophin gene transcribed from different promoters in neuronal and glial cells. Nature (1990) 1.54
Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet (2006) 1.30
A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene. Mol Ther (2008) 1.27
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum Mol Genet (2008) 1.19
Construction of a novel human artificial chromosome vector for gene delivery. Biochem Biophys Res Commun (2004) 1.10
Artificial and engineered chromosomes: non-integrating vectors for gene therapy. Trends Mol Med (2005) 1.04
Correction of a genetic defect in multipotent germline stem cells using a human artificial chromosome. Gene Ther (2008) 1.03
Transfer of human artificial chromosome vectors into stem cells. Reprod Biomed Online (2008) 1.00
Using therapeutic cloning to fight human disease: a conundrum or reality? Stem Cells (2006) 0.94
Dystrophin in control and mdx retina. Brain Dev (1991) 0.84
Cloning: mining the secrets of the egg. Nature (2006) 0.80
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2007) 21.93
The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell (2003) 17.72
Generation of mouse induced pluripotent stem cells without viral vectors. Science (2008) 15.25
Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science (2008) 10.55
Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature (2009) 9.75
A more efficient method to generate integration-free human iPS cells. Nat Methods (2011) 7.39
Nanog is the gateway to the pluripotent ground state. Cell (2009) 7.27
Retracted Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (2004) 7.21
Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc (2007) 7.01
Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol (2009) 6.39
Dicer is essential for formation of the heterochromatin structure in vertebrate cells. Nat Cell Biol (2004) 5.92
Rac1 and Cdc42 capture microtubules through IQGAP1 and CLIP-170. Cell (2002) 4.68
Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell (2009) 4.38
Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell polarization and migration. Dev Cell (2004) 4.05
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
Generation of pluripotent stem cells from neonatal mouse testis. Cell (2004) 3.95
mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol (2004) 3.72
Reactivation of the paternal X chromosome in early mouse embryos. Science (2004) 3.59
Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation. Nat Genet (2004) 3.56
Roles of Rho-family GTPases in cell polarisation and directional migration. Curr Opin Cell Biol (2003) 3.31
Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation (2008) 3.11
Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature (2003) 3.08
Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell (2009) 3.03
CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell (2006) 2.93
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med (2012) 2.80
Generation of retinal cells from mouse and human induced pluripotent stem cells. Neurosci Lett (2009) 2.75
Shisa promotes head formation through the inhibition of receptor protein maturation for the caudalizing factors, Wnt and FGF. Cell (2005) 2.61
Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci U S A (2010) 2.52
Transcriptional repression and DNA hypermethylation of a small set of ES cell marker genes in male germline stem cells. BMC Dev Biol (2006) 2.50
Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol (2005) 2.47
Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A (2010) 2.44
Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol Cell Biol (2003) 2.40
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell (2013) 2.32
Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet (2011) 2.26
An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells (2013) 2.18
iPS cells: a game changer for future medicine. EMBO J (2014) 2.15
Telomere lengths are characteristic in each human individual. Exp Gerontol (2002) 2.13
Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature (2011) 2.11
Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci (2011) 2.09
Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci U S A (2011) 2.09
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med (2010) 2.08
Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability. Proc Natl Acad Sci U S A (2009) 2.00
Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One (2011) 1.95
Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc (2010) 1.93
Asb4, Ata3, and Dcn are novel imprinted genes identified by high-throughput screening using RIKEN cDNA microarray. Biochem Biophys Res Commun (2002) 1.92
Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech (2011) 1.87
Discovery of imprinted transcripts in the mouse transcriptome using large-scale expression profiling. Genome Res (2003) 1.82
Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81
Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res (2013) 1.80
Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med (2012) 1.78
Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 1.78
MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther (2011) 1.77
miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY) (2010) 1.76
IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells (2008) 1.75
Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome. Proc Natl Acad Sci U S A (2004) 1.72
Predominant maternal expression of the mouse Atp10c in hippocampus and olfactory bulb. J Hum Genet (2003) 1.72
Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell (2013) 1.70
New advances in iPS cell research do not obviate the need for human embryonic stem cells. Cell Stem Cell (2007) 1.68
Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol (2008) 1.68
Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest (2010) 1.66
Genetic and epigenetic properties of mouse male germline stem cells during long-term culture. Development (2005) 1.65
Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol (2007) 1.65
Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem (2005) 1.64
Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J Biol Chem (2004) 1.58
Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A (2003) 1.57
Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci Res (2005) 1.57
Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. Circulation (2010) 1.54
Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts. Genes Cells (2009) 1.53
Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun (2003) 1.53
Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells. Atherosclerosis (2010) 1.52